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Abstract
Purpose: Corrected T1 (cT1) value is a novel MRI-based
quantitative metric for assessing a composite of liver
inflammation and fibrosis. It has been shown to distin-
guish between non-alcoholic fatty liver disease (NAFL)
and non-alcoholic steatohepatitis. However, these studies
were conducted in patients at high risk for liver disease.
This study establishes the normal reference range of cT1
values for a large UK population, and assesses interac-
tions of age and gender.
Methods: MR data were acquired on a 1.5 T system as
part of the UK Biobank Imaging Enhancement study.
Measures for Proton Density Fat Fraction and cT1 were
calculated from the MRI data using a multiparametric
MRI software application. Data that did not meet
quality criteria were excluded from further analysis.
Inter and intra-reader variability was estimated in a set
of data. A cohort at low risk for NAFL was identified by
excluding individuals with BMI ‡ 25 kg/m2 and PDFF ‡
5%. Of the 2816 participants with data of suitable qual-
ity, 1037 (37%) were classified as at low risk.
Results: The cT1 values in the low-risk population
ranged from 573 to 852 ms with a median of 666 ms
and interquartile range from 643 to 694 ms. Iron
correction of T1 was necessary in 36.5% of this reference
population. Age and gender had minimal effect on cT1
values.
Conclusion: The majority of cT1 values are tightly
clustered in a population at low risk for NAFL,
suggesting it has the potential to serve as a new
quantitative imaging biomarker for studies of liver
health and disease.
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Liver disease is rapidly becoming one of the major causes
of mortality in the Western world, fueled by the growing
pandemic of obesity. There is increasing awareness that
excessive liver fat (termed steatosis, or non-alcoholic
fatty liver—NAFL) is also a precursor to liver inﬂam-
mation (non-alcoholic steatohepatitis—NASH), ﬁbrosis,
and cirrhosis, which are also associated with cardiovas-
cular disease, further contributing to the overall mor-
tality [1–3]. Moreover, NASH and liver fibrosis
predispose individuals to hepatocellular carcinoma [4, 5].
Williams et al. showed that the United States prevalence
rates of NAFL and NASH were 46% and 12%, respec-
tively [6]. Unfortunately, liver disease is frequently not
detected until clinical symptoms appear, when fewer
treatment options exist, and many of those with liver
disease are unaware of the fact [7]. It is therefore essential
to identify those individuals at highest risk of progressing
to cirrhosis while the disease is in its early stages.
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Multiparametric magnetic resonance imaging (MRI)
of the liver has been shown to have prognostic capabil-
ities in the setting of chronic liver disease, as well as being
able to detect early stages of liver ﬁbrosis [8]. This
technique has been validated against biopsy and has an
advantage over conventional MRI or ultrasound in that
it is quantitative, referring to absolute rather than rela-
tive values. Moreover, parametric maps of proton den-
sity fat fraction or T1 relaxation times (a measure of free
water content) can be compared objectively across pop-
ulations and longitudinally within individuals. This
multiparametric MRI data can be processed to provide
key quantitative liver metrics, including liver fat, iron
content, and the novel Liver Inflammation and Fibrosis
(LIF) score, which is based on iron corrected T1 (cT1).
cT1 is a novel imaging biomarker based on T1 mapping
technology, which takes advantage of the increases in
extracellular tissue fluid that occur in response to
inflammation and fibrosis, while also correcting for ele-
vated iron content. In a recent clinical trial using a pre-
standardized version of the technology, high cT1 values
(> 875 ms) were shown to strongly predict liver-related
clinical outcomes (e.g., hepatic encephalopathy, variceal
bleeding, ascites, death) [9]. Although not definitively
established, the generally accepted upper limit of normal
for liver fat content, as measured by proton density fat
fraction (PDFF), is approximately 5% [10–12]. Similar
population-based ranges and cut-off data for the cT1
biomarker are needed. There is a need for an under-
standing of normality and abnormality in the context of
NAFL and NASH, to establish which populations are at
risk, and, future criteria for treatment with a variety of
NASH agents, which are currently being developed by
the pharmaceutical industry.
The purpose of this article is to provide a set of ref-
erence values for cT1 within a population nominally at
low risk for fatty liver disease. To this end, we use data
acquired as part of the largest prospective population
study in history, UK Biobank [13–15]. In this study, we
identify the subset of the UK Biobank cohort at ‘low
risk’ for NAFL and NASH and describe the range of cT1
values in this population. We also define the effects of
age and gender on cT1 values.
Materials and methods
Study design and population
This was a retrospective study of MR data acquired as
part of the UK Biobank imaging enhancement study
between August 2014 and August 2015. The UK Bio-
bank study recruited 500,000 volunteers between the ages
of 40 and 69 years from across the UK between April
2007 and August 2010, based on proximity to the 21
assessment centers and registration with the National
Health Service [16]. A random subset of 100,000 subjects
are being invited to participate in the imaging sub-study
that images the brain, heart, abdomen, bones, and car-
otid arteries of these subjects [17]. At the time this ret-
rospective study was performed, scan data for 2921
subjects were available for processing. 6000 subjects had
been scanned in the pilot phase, but following review of
the pilot data, the MR sequence was further optimized.
The 2921 subjects in this study were scanned between
January 4, 2016 and September 8, 2016. The study pro-
tocol is shown in Fig. 1. Of the 2921 datasets available
for processing, 105 (~ 4%) were deemed incomplete or of
insufficient quality. As outlined in Fig. 1, the most
common reason for failure was generally related to mo-
tion artifacts. This left 2816 (~ 96%) datasets that were
analyzed to obtain quantities for liver fat fraction (pro-
ton density fat fraction—PDFF) and fibroinflammatory
disease (cT1). Accompanying participant data [gender,
age, and body mass index (BMI)] were acquired through
a data access application to UK Biobank (Application
9914). The reference population was defined by exclud-
ing those participants with either PDFF ‡ 5%, or
BMI ‡ 25 kg/m2. Data were analyzed for the reference
cohort, comparison cohorts with PDFF ‡ 5% and/or
BMI ‡ 25 kg/m2, as well as separately for gender and
age ranges of 40–49, 50–59, 60–69, and ‡ 70 years.
Fig. 1. Study design.
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Imaging protocol
Image acquisition took place at the dedicated Biobank
imaging Centre at Cheadle (UK) using a Siemens 1.5 T
MAGNETOM Aera, syngo MR D13. Two sequences
were used to acquire data: a Shortened Modiﬁed Look
Locker Inversion (ShMOLLI) [18] and a multiecho
spoiled-gradient-echo [19].
A single transverse slice, located at the porta hepatis,
was chosen to represent the liver for both acquisitions.
Acquisition was performed in end-expiration breath-hold
and without the aid of any contrast agent injection. This
slice-based methodology has previously been shown to
correlate well with histology [8] and predict liver-related
outcomes [9]. The rapid acquisition time (£ 3 min) was
an essential requirement to meet the high-throughput
demands of the UK Biobank study [14].
The ShMOLLI sequence is based on an ECG-Trig-
gered method that samples the T1 recovery curve in three
epochs over 9 heartbeats using single-shot balanced stea-
dy-state free precession (bSSFP) acquisitions with the
following parameters: TR = 4.8 ms, TE = 1.93 ms, ﬂip
angle = 35, slice thickness = 8 mm, ﬁeld of view =
44 9 33 cm2, acquisition matrix = 192 9 144 (zero
padded to 384 9 288) yielding an interpolated pixel size of
1.1 mm 9 1.1 mm. Parallel imaging acceleration factor of
2 with 24 reference lines was used with the integrated
Parallel Acquisition Technique (iPAT). Trigger delay was
set to 50 ms and the first ShMOLLI inversion time (TI)
was set to 170 ms with five increments of 50 ms each.
The T1 relaxation map acquired using the ShMOLLI
sequence is affected by excess iron, which reduces T1.
Thus, an algorithm removes the bias introduced by ex-
cess iron, which can be calculated from the T2* maps
[20], from the T1 measurements, providing the iron
corrected T1 (cT1) [21]. The specific methodology of this
algorithm has been described previously [8], and simu-
lates the T1 that would be measured on a 3T scanner in
the absence of excess liver iron, with a T2* of 23.1 ms (at
1.5T) used as the threshold for excess iron.
The multiecho spoiled-gradient-echo chemical shift
encoded acquisition was used to calculate T2* and PDFF
maps of the liver. The following parameters were used:
ﬁeld of view = 40 9 40 cm2, acquisition matrix = 160
9 160 yielding a voxel size of 2.5 mm 9 2.5 mm, slice
thickness = 6 mm, flip angle = 20, TR = 27 ms, and
2 signal averages, requiring 9 s to acquire. Ten echo
times were selected such that the signals from fat and
water were in phase and out of phase at 1.5T (TE =
2.38, 4.76, 7.14, 9.52, 11.90, 14.28, 16.66, 19.04, 21.42,
and 23.80 ms). For PDFF, a three-point DIXON tech-
nique [22, 23] was used on the complex data from the
second, third, and fourth echoes. This technique takes
into account magnetic field inhomogeneity and assumes
that the fat has a single-peak frequency. The flip angle of
20 degrees leads to some T1 bias, which has been shown
to reduce PDFF values by a factor of 1.2, relative to
using a lower flip angle with an in-house implementation
of the IDEAL methodology [24]. For R2* estimation, an
exponential signal decay model [25] was fitted to the
magnitude data from the second, fourth, sixth, eight, and
tenth echo times (i.e., the five in-phase echoes).
Post-processing
RawMR data were sent to a central reporting laboratory
and transferred to an individual workstation (Mac OSX)
for analysis. All processed data are available through
application to UK Biobank.
Image analysis
Image data were analyzed, blinded to all other subject
data, using LiverMultiScan Discover software [22]. For
each T2*, cT1, and PDFF image, three circular regions
of interest (ROIs) of 15 mm diameter were selected, and
a mean value from the pixels within the ROI was cal-
culated. ROIs were manually placed by a trained analyst
to capture the distribution of image intensities within the
liver and avoid MRI artifacts, if present. The T2* and T1
values together provide the cT1. Characterization of liver
fat (PDFF) in the UK Biobank cohort has been previ-
ously reported [26].
Inter- and intra-reader variability
Inter- and intra-reader variability in ROI placement was
determined in an initial set of MR datasets collected
from the UK Biobank imaging cohort. 39 MR datasets
were selected to encompass the range of cT1 and PDFF
values found in the population. Six technologists ana-
lyzed the anonymized datasets on day one and then again
on day four. Intra and inter-reader agreement was cal-
culated using intra-class correlation (two-way mixed
model with ﬁxed effects, referred to as Class 3 in the
original work) [27] and Bland–Altman analyses [28].
Two sets of Bland–Altman analyses were performed.
The ﬁrst set compared values acquired on day one and
day four for each of the six technologists. The mean and
range of the limits of agreement from these six Bland–
Altman are reported to demonstrate the intra-rater reli-
ability. The second set of Bland–Altman analyses was an
all-against-all analysis of data from day one. The results
of each technologist were compared to those of each
other technologist. The mean and range of the limits of
agreement from these ﬁfteen Bland–Altman analyses are
reported to demonstrate the inter-rater reliability.
Statistical analysis
Normality of BMI, PDFF, and cT1 distributions was
tested using D’Agostino–Pearson and Kruskal–Wallis
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tests. Summary data for cT1 are presented as medians
with interquartile ranges (IQR) and means with standard
deviation (SD). Mann–Whitney tests were used to test
for statistically signiﬁcant differences between groups.
Correlation analysis was performed using linear regres-
sion.
Case studies
Case studies are provided in the Appendix. Case studies
given in Figs. 4, 5, 7, and 8 in Appendix are from the
Patient Understanding of LiverMultiScan trial (Clini-
calTrials.gov Identifier: NCT02877602) performed at the
Oxford University NHS Foundation Trust, UK. The
case study in Fig. 6 is from Massachusetts General
Hospital, US.
Results
cT1 distribution in low-risk subpopulation
Figure 2A shows example cT1 images. Figure 2B shows
the range of cT1 values in the reference population. cT1
values are non-normally distributed with a median value
of 666.0 ms (IQR 643.3–694.8 ms; 2.5–97.5 percentiles of
600–763 ms) (Fig. 2). Subcohorts were defined as non-
overweight (BMI < 25 kg/m2, 39% of the total cohort),
non-steatotic (PDFF < 5%, 76% of the total cohort),
and ‘reference’ (both non-overweight (BMI < 25 kg/m2)
and free from steatosis (PDFF < 5%), 37% of the total
cohort). Summary statistics for cT1 in these three cohorts
are shown in Table 1. For comparison, Table 1 also
describes the same statistics for three additional cohorts:
non-overweight but steatotic (median cT1 of 712.5 ms),
overweight but non-steatotic (median cT1 of 681.7 ms),
and overweight and steatotic (median cT1 of 744.7). In
each of these higher-risk cohorts, the median cT1 is
significantly higher than the reference cohort
(p < 0.0001). T2* values for 36.5% of the reference
population (379/1037) were sufficiently low (< 23.1 ms;
corresponding to elevated iron concentration) to require
iron correction of T1 (cT1). For comparison, 42.2% of
the original population (1187/2816) required iron cor-
rection of T1. It should be noted that this threshold for
iron correction is lower than that which would be con-
sidered clinically significant iron overload.
In the original population, cT1 showed a signiﬁcant
but weak correlation with PDFF (r2 = 0.45;
p < 0.0001) and a significant but very weak correlation
with T2* (r2 = 0.004; p < 0.001). PDFF showed a sig-
nificant but very weak correlation with T2* (r2 = 0.05;
p < 0.0001).
Gender and age characteristics of reference
subpopulation
Table 2 and Fig. 3 show the breakdown of cT1 values by
age and gender in the reference cohort. Overall, the effect
size of age and gender was minimal. The cT1 values were
lower in women than men, but not significantly so (me-
dian 664.5 vs. 671.7 ms, p = 0.11, Mann–Whitney test).
Median cT1 values in different age groups showed min-
imal variation (from 662.4 to 691.9 ms).
Among men, there was no difference between age
groups. However, among women, there was a signiﬁcant,
though numerically small (median 692.4 vs. 665.8 ms),
difference between the ages of 40–49 years and
60–69 years (p < 0.0005) (Fig. 3). Among women, there
was a negative correlation between age and cT1 (r =
- 0.12, slope (95% CI) - 0.67 ms/year (- 1.12 to
- 0.23), p = 0.0029). No such correlation was evident
Fig. 2. Range of cT1 in the reference population. A Example images with three different cT1 values. B Beeswarm plot showing
distribution of cT1 values in the reference population, with median (666.0 ms) and IQR (643.3–694.8 ms) shown.
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among men. Compared to the whole Biobank popula-
tion, this low-risk cohort is older and has a higher pro-
portion of women (Table 3).
Inter- and intra-reader variation in cT1
and PDFF
Intra-reader reproducibility for cT1 and PDFF readings
is summarized in Table 4. Intra-class correlation was
very high for both cT1 and PDFF. Intra-rater limits of
agreement were in the range of ± 25 ms (cT1) and ±
0.5% (PDFF) for the six technologists. Inter-rater limits
of agreement spanned approximately 60 ms (i.e., upper
and lower limits of ± 30 ms) and 1.2% (i.e., upper and
lower limits of ± 0.6%) for cT1 and PDFF ,respectively,
and the magnitude of the largest bias between any pair of
technologists was 15 ms for cT1 and 0.08% for PDFF.
For individual readers reading cT1 data on different
days, the intra-class correlation was 0.93 (95% conﬁdence
Table 1. Summary statistics for cT1 (ms) in cohorts defined by BMI and PDFF
n % of total cohort (2816) Min 25th Percentile Median 75th Percentile Max
BMI < 25 kg/m2 and PDFF < 5% 1037 37 573.4 643.3 666.0 694.8 852.2
BMI < 25 kg/m2 1100 39 573.4 644.7 667.6 697.9 882.7
PDFF < 5% 2142 76 554.5 649.3 674.0 703.6 852.2
BMI < 25 kg/m2 and PDFF ‡ 5% 63 2 648.4 684.5 712.5 748.2 882.7
BMI ‡ 25 kg/m2 and PDFF < 5% 1104 39 554.5 657.5 681.7 711.0 844.2
BMI ‡ 25 kg/m2 and PDFF ‡ 5% 611 22 618.8 711.0 744.7 792.4 990.5
The reference population is defined as BMI <25 kg/m2 and PDFF < 5%
Table 2. Median cT1 of reference cohort by age and gender
Group Number Median cT1 (IQR) by age group
40–49 years 50–59 years 60–69 years 70–79 years All ages
All 1037 691.9 (650.5–721.9) 662.4 (644.1–692.5) 665.8 (640.2–691.5) 667.7 (644.6–695.9) 666.0 (643.3–694.8)
Male 384 685.3 (632.6–726) 658.5 (637.3–684.4) 673.2 (647.6–702.7) 657.1 (641.8–687.9) 671.7 (643.6–698.1)
Female 653 692.4 (654.5–711.8) 663.6 (646.5–695.6) 661.5 (638.2–682.8) 678.2 (650.3–699.8) 664.5 (643.3–692.2)
Table 3. Gender and age profiles of total and reference populations






All (n = 2816)
Male 48 1.1:1 62.1 7.1
Female 52 61.2 6.8
Reference (n = 1037)
Male 37 1.70:1 62.0 7.1
Female 63 61.0 6.8
Fig. 3. Boxplots showing distribution of cT1 in the reference population by age and gender. 62 individuals are not plotted as
their age was missing from the dataset. Outliers not shown.
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interval 0.89–0.96). For individual readers reading the
cT1 data on different days, the mean upper and lower
limits of agreement from the six intra-rater analyses were
20 ms (range 17–25 ms) and - 25 ms (range - 30 to
- 17 ms). For the ﬁfteen inter-rater analyses, the mean
upper and lower limits of agreement were 31 ms (range
20–55 ms) and - 32 ms (range - 52 to - 18 ms), and
the mean bias was 0 ms (range - 13 to 15 ms).
For individual readers reading PDFF data on dif-
ferent days, the intra-class correlation was 0.97 (95% CI
0.96–0.99). For individual readers reading the PDFF
data on different days, the mean upper and lower limits
of agreement for the six intra-rater analyses were 0.52%
(range 0.37–0.61%) and - 0.48% (range - 0.62 to
- 0.44%). For the ﬁfteen inter-rater analyses, the mean
upper and lower limits of agreement were 0.59% (range
0.35–0.78%) and - 0.57% (range - 0.77 to - 0.40%),
and the mean bias was 0.01% (range - 0.08 to 0.08%).
Discussion
Liver disease is a growing clinical problem being fuelled
by the obesity epidemic. Obesity is a risk factor for fatty
liver disease, which has been deﬁned as hepatic fat con-
tent greater than 5% [12]. Importantly, liver disease,
unlike chronic pulmonary, cardiac, or neurodegenerative
diseases, is usually asymptomatic, with few physical
manifestations until the development of cirrhosis; thus,
detection and case-finding cannot be based on clinical
history and examination alone. Scaglione et al. estimated
the prevalence of cirrhosis in the United States to be
approximately 0.27% from NHANES and death registry
data 1999–2010, corresponding to 633,323 adults. Mor-
tality was 26.4% per 2-year interval in cirrhosis compared
with 8.4% in propensity-matched controls [7]. Identifying
those individuals at risk of cirrhosis before it develops
would be of enormous utility.
Deﬁning normal ranges for new biomarkers is
essential if they are to be used to assess the presence,
absence, or change of disease over time. There is an
additional need for objective biomarkers to determine
the efﬁcacy of potential treatments, as there are currently
no licensed pharmaceutical treatments for NASH. Fur-
thermore, natural history studies of liver disease have
been limited to small cohorts in the past because the only
way of assessing liver disease across the spectrum from
healthy to cirrhosis was with serial liver biopsy. In 1990,
Powell et al. studied 42 NAFL patients with serial liver
biopsies for a median of 4.5 years (range 1.5–20 years)
and concluded that NASH is a cause of hepatic inﬂam-
mation histologically resembling that of alcohol-induced
liver disease but usually slowly progressive and of low-
grade severity [29]. Ekstedt et al. studied 129 patients
with biopsy-proven NAFL, whom they followed over
13 years, with repeat biopsies in 88 [30]. Disease pro-
gression in the liver occurred in 41% of the repeat biopsy
patients, while 78% of the whole cohort developed dia-
betes, 19% died, and a further 4% had end-stage liver
failure. However, there is no natural history study of
liver-related outcomes in a low-risk population that can
be used as a comparison. cT1 values have been shown to
predict clinical outcomes in chronic liver disease patients
[9]. The whole UK Biobank cohort will be censured at 3
yearly intervals to collect clinical outcomes. Our
hypothesis is that those participants with high cT1 values
are more likely to suffer clinical outcomes.
Our study also shows that age and gender have a
negligible inﬂuence on cT1, with a maximum median
value variation of 24.1 (658.3 vs. 692.4 ms). This suggests
that, in practice, a correction of cT1 for age and gender
may not be necessary. The small, but statistically sig-
niﬁcant, increase in cT1 in the youngest female group
(age 40–49 years), which can be assumed to be largely
pre-menopausal, is most likely explained by the effect of
higher estrogen levels on liver water content, as previ-
ously described [31, 32].
While cT1 showed statistically signiﬁcant correlations
with both PDFF and T2*, these were weak (r2 = 0.45)
and very weak (r2 = 0.004), respectively. Simulation
studies have suggested a sequence-dependent positive
effect of high fat on T1 [33], which may contribute to this
weak correlation; however, steatosis often co-occurs with
inflammation in liver diseases such as NASH [2] and
viral hepatitis [34], based on histological assessment.
Further studies are required to tease apart the relative
contributions of these effects.
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Intra-rater limits of agreement are a summary of six Bland–Altman analyses. Inter-rater limits of agreement are a summary of fifteen Bland–Altman
analyses
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In this study, we describe the expected values of the
cT1 in a healthy population, deﬁned as a cohort at low
risk for NAFL by the absence of a BMI ‡ 25 kg/m2 and
hepatic steatosis. The value of this cohort is as a com-
parator for populations with greater likelihood of dis-
ease, for whom it can serve as a baseline.
Limitations
The pilot phase of the UK Biobank imaging enhance-
ment study has shown that high-throughput phenotyping
is feasible. However, as MR methods develop (e.g.,
multispectral measurement of PDFF), further reﬁnement
of these techniques will need testing and implementing.
The current ROI-based analysis from a single slice may
have limitations in very heterogeneous disease distribu-
tions. In such cases, a histogram-based analysis may be
more appropriate. A whole liver evaluation would allow
better characterization of heterogeneity and reduce
sampling errors; however, given the extremely high
throughput of the study, there was insufﬁcient time in the
protocol to scan the whole liver. Given the UK Biobank
subjects were drawn from a nominally healthy popula-
tion, this is unlikely to signiﬁcantly impact the conclu-
sions of this study. The imaging data used in this study
were acquired on a single scanner and therefore does not
include any potential variability that may occur between
different MRI scanners; however, computation of cT1
explicitly accounts for differences in ﬁeld strength and T1
mapping implementation (LiverMultiScan version 2.0,
Perspectum Diagnostics Ltd, UK). Approximately 4% of
scans in this normal population were incomplete or of
insufﬁcient quantity, and this may increase when applied
to an actual patient population.
The age range of the population is restricted to those
of 40 years of age and above, so this population may not
be representative of younger people. Also, the current
deﬁnition of healthy solely in terms of BMI and hepatic
steatosis does not account for other factors that can
inﬂuence liver health such as alcohol and drug use, ge-
netic predisposition, and infection. Information on eth-
nicity and other socio-economic factors is becoming
available, so their inﬂuences should also be explored. As
further UK Biobank data are released, more reﬁned
analyses will become possible.
Conclusions
This article describes, for the ﬁrst time, the reference range
of cT1 values as deﬁned in a large population at low risk
for NAFL. The range presented here has the potential,
where desirable, to serve as a benchmark of normality for
future studies assessing NAFL with PDFF and cT1.
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Appendix
See Figs. 4, 5, 6, 7, and 8.
Fig. 4. Example case provided for an overview of the
software results sheet. The results sheet depicts source
images (A) with circular regions of interest (ROI) drawn (blue
circles). The statistics summary (B) provides values for
calculated proton density fat fraction (PDFF), T2*, and cT1
(with normal reference ranges for each). The cT1 value is
calculated from a circular ROI which should be placed within
hepatic parenchyma, avoiding any vessels. The results
sheet also includes a colormap (C) for a pictorial
representation of cT1.
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Fig. 5. Cases 1 and 2: Patient 1 is a 64-year-old female with
non-alcoholic steatohepatitis and patient 2 is a 42-year-old
male with steatosis. Axial (B, E) and coronal (C, F) T2*
weighted images of the liver provide anatomical information
for each patient, but no sensitivity to detect underlying
parenchymal disease. Results sheets for patient 1 (A) and 2
(D) demonstrate that both patients have elevated PDFF
values, 15.3% for patient 1 and 8.2% for patient 2. An
advantage of this method is that the level of fat, as well as its
burden on the hepatic parenchyma, is instantly assessed. The
colormaps demonstrate that the cT1 value of patient 1 is
notably higher than patient 2, indicating a greater degree of
inflammation and fibrosis. Patient 2 has a mildly elevated cT1
value, but has the opportunity for intervention (medical and/or
lifestyle) before potentially progressing to the cT1 value of
patient 1.
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Fig. 6. Case 3: A 47-year-old female with polycystic liver
disease listed for liver transplant. MRI was obtained to assess
hepatic cyst burden and integrity of the remaining hepatic
parenchyma. Anatomical axial (A) and coronal (B) T2-
weighted images of the abdomen demonstrate innumerable
cysts throughout the liver. Results sheet (C) demonstrates
that liver fat, T2*, and cT1 are all within normal limits. The
results are also displayed in pictorial format with the areas of
remaining hepatic parenchyma coded in green (normal cT1)
on the colormap. This case uniquely exemplifies the
advantage of this methodology over other techniques to
assess the pathophysiological state of hepatic parenchyma,
such as ultrasound or MR elastography. These elastography
methods would produce spurious results in this setting, as the
extensive cyst burden would alter the acoustic wave
propagation through the liver.
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Fig. 7. Case 4: A 79-year-old male with autoimmune
hepatitis (AIH). Axial (A) and coronal (B) images of the liver
provide anatomical information, but are unable to provide any
clarity regarding the underlying pathophysiologic process.
Results sheet (C) shows the complexity of this individual’s
disease. In a pattern characteristic of AIH, the spread of
fibroinflammatory disease is heterogeneous with some areas
clearly demonstrating higher cT1 values than others.
Measuring cT1 in a single circular region of interest would
yield varying results (e.g., normal in the right lobe as shown
here, and abnormal in the left lobe). The colormap image also
clearly demonstrates the size of the complicating ascites
(purple/pink), a source of discomfort for the patient.
Consequently, the results sheet and images provide a
comprehensive assessment of this patient’s complex
disease.
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Fig. 8. Case 5: A 51-year-old male who had lived with
hepatitis C virus infection since 1984. Patient had failed to get
a sustained virologic response (SVR) after interferon
treatment in 2014, and is now undergoing treatment with
ledipasvir/sofosbuvir. Axial (B, E) and coronal (C, F) T2*-
weighted images of the liver provide anatomical information
but are unable to provide further tissue characterization.
Result sheets from examinations at the 1st (A) and 7th
(B) weeks of treatment are provided. These clearly show
response to the treatment, with the cT1 value and cT1
colormap improving over the course of treatment. Patient
achieved SVR at 12 and 24 weeks.
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